JP2020114837A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020114837A5 JP2020114837A5 JP2020049116A JP2020049116A JP2020114837A5 JP 2020114837 A5 JP2020114837 A5 JP 2020114837A5 JP 2020049116 A JP2020049116 A JP 2020049116A JP 2020049116 A JP2020049116 A JP 2020049116A JP 2020114837 A5 JP2020114837 A5 JP 2020114837A5
- Authority
- JP
- Japan
- Prior art keywords
- approximately
- administered
- cell immunotherapy
- dose
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762480414P | 2017-04-01 | 2017-04-01 | |
| US62/480,414 | 2017-04-01 | ||
| US201862613697P | 2018-01-04 | 2018-01-04 | |
| US62/613,697 | 2018-01-04 | ||
| US201862624454P | 2018-01-31 | 2018-01-31 | |
| US62/624,454 | 2018-01-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551293A Division JP6748221B2 (ja) | 2017-04-01 | 2018-03-30 | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020114837A JP2020114837A (ja) | 2020-07-30 |
| JP2020114837A5 true JP2020114837A5 (cg-RX-API-DMAC10.html) | 2021-05-06 |
| JP7162632B2 JP7162632B2 (ja) | 2022-10-28 |
Family
ID=62111173
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551293A Active JP6748221B2 (ja) | 2017-04-01 | 2018-03-30 | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
| JP2020049116A Active JP7162632B2 (ja) | 2017-04-01 | 2020-03-19 | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018551293A Active JP6748221B2 (ja) | 2017-04-01 | 2018-03-30 | 細胞免疫療法前の細胞毒性プレコンディショニングの代替 |
Country Status (13)
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10426740B1 (en) | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| WO2025019711A2 (en) * | 2023-07-19 | 2025-01-23 | Dermtech, Inc. | Predicting therapeutic response based on biomarker signatures |
| CN110475571B (zh) | 2017-04-01 | 2023-04-04 | Avm生物技术有限责任公司 | 细胞免疫疗法前细胞毒性预调理的替代 |
| CN110944689B (zh) | 2017-06-07 | 2022-12-09 | 施菲姆德控股有限责任公司 | 血管内流体运动设备、系统和使用方法 |
| WO2019094963A1 (en) | 2017-11-13 | 2019-05-16 | Shifamed Holdings, Llc | Intravascular fluid movement devices, systems, and methods of use |
| WO2019152875A1 (en) | 2018-02-01 | 2019-08-08 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use and manufacture |
| KR20210011919A (ko) | 2018-04-17 | 2021-02-02 | 셀덱스 쎄라퓨틱스, 인크. | 항-cd27 항체 및 항-pd-l1 항체 및 이중특이적 작제물 |
| US12161857B2 (en) | 2018-07-31 | 2024-12-10 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use |
| EP3488851A1 (en) | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
| EP3632446B3 (en) | 2018-10-03 | 2024-01-24 | AVM Biotechnology, LLC | Immunoablative therapies |
| WO2020073047A1 (en) | 2018-10-05 | 2020-04-09 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of use |
| BR112021009365A2 (pt) * | 2018-11-14 | 2021-08-10 | Avm Biotechnology, Llc | formulação de glicocorticoide estável |
| KR102946444B1 (ko) * | 2018-11-16 | 2026-04-02 | 라파 쎄라퓨틱스 엘엘씨 | 제조된 t 세포로 암을 치료하는 방법 |
| US20220016168A1 (en) * | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
| KR20250116790A (ko) | 2018-12-12 | 2025-08-01 | 카이트 파마 인코포레이티드 | 키메라 항원 수용체 및 car-t 세포 및 사용 방법 |
| US11964145B2 (en) | 2019-07-12 | 2024-04-23 | Shifamed Holdings, Llc | Intravascular blood pumps and methods of manufacture and use |
| WO2021016372A1 (en) | 2019-07-22 | 2021-01-28 | Shifamed Holdings, Llc | Intravascular blood pumps with struts and methods of use and manufacture |
| EP4010046B1 (en) | 2019-08-07 | 2026-07-15 | Supira Medical, Inc. | Catheter blood pumps and collapsible pump housings |
| WO2021062270A1 (en) | 2019-09-25 | 2021-04-01 | Shifamed Holdings, Llc | Catheter blood pumps and collapsible pump housings |
| EP4782050A1 (en) | 2019-09-25 | 2026-07-29 | Supira Medical, Inc. | Catheter blood pumps and collapsible blood conduits |
| EP4034192B1 (en) | 2019-09-25 | 2025-12-24 | Supira Medical, Inc. | Intravascular blood pump systems and methods of use and control thereof |
| IL292665B2 (en) * | 2019-11-06 | 2026-02-01 | Kite Pharma Inc | Chimeric antigen receptor T cell therapy |
| EP4072650A4 (en) | 2019-12-11 | 2024-01-10 | Shifamed Holdings, LLC | Descending aorta and vena cava blood pumps |
| WO2021127503A1 (en) | 2019-12-19 | 2021-06-24 | Shifamed Holdings, Llc | Intravascular blood pumps, motors, and fluid control |
| CN113189340A (zh) * | 2020-01-14 | 2021-07-30 | 中国医学科学院基础医学研究所 | 细胞焦亡通路在细胞治疗中的用途 |
| WO2021168375A1 (en) * | 2020-02-20 | 2021-08-26 | Kite Pharma, Inc. | Chimeric antigen receptor t cell therapy |
| KR20220148859A (ko) | 2020-02-28 | 2022-11-07 | 에이브이엠 바이오테크놀로지, 엘엘씨 | 림프구 집단 및 이를 생산하는 방법 |
| CN111443210B (zh) * | 2020-04-10 | 2023-09-22 | 青海大学附属医院 | 泡型包虫病早期诊疗生物标志物及其应用 |
| CN115989038A (zh) * | 2020-04-10 | 2023-04-18 | 北卡罗莱纳州立大学 | 使用材料支架的增强的哺乳动物细胞病毒转导 |
| US20230172950A1 (en) | 2020-04-29 | 2023-06-08 | Avm Biotechnology, Llc | Glucocorticoid Receptor (GR) Modulators for Treating a SARS-COV-2 Virus |
| WO2021231806A1 (en) | 2020-05-13 | 2021-11-18 | Rapa Therapeutics, Llc | Antigen presenting t cells, sensitized, manufactured t cells and methods of treatment using the same |
| WO2021247000A1 (en) | 2020-06-01 | 2021-12-09 | Avm Biotechnology, Llc | Methods of treatment using icam-modulating agents |
| CN113797313A (zh) * | 2020-06-11 | 2021-12-17 | 华北制药集团新药研究开发有限责任公司 | 卡非佐米作为冠状病毒广谱抑制剂的新用途 |
| WO2022049572A1 (en) * | 2020-09-01 | 2022-03-10 | The National Institute for Biotechnology in the Negev Ltd. | Immune system restoration by cell therapy |
| CN113322233A (zh) * | 2021-04-19 | 2021-08-31 | 格源致善(上海)生物科技有限公司 | 一种改进的基于新生抗原反应性t细胞的制备方法及应用 |
| EP4326286A4 (en) * | 2021-04-23 | 2025-03-12 | Myeloid Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR CONDITIONING PATIENTS FOR CELL THERAPY |
| CN115947793B (zh) * | 2021-08-13 | 2023-09-26 | 中国人民解放军总医院 | 靶向pd-l1的超高亲和力小蛋白及用途 |
| CA3229529A1 (en) | 2021-09-01 | 2023-03-09 | Avm Biotechnology, Llc | Lymphocyte population and methods for producing same |
| CN114031678A (zh) * | 2021-12-08 | 2022-02-11 | 中国科学院新疆理化技术研究所 | 一种条斑钳蝎毒素多肽组分的制备方法及其应用 |
| CN114767828A (zh) * | 2022-04-25 | 2022-07-22 | 中国人民解放军海军军医大学 | 伊沙佐米在制备抗蜱传脑炎病毒、西尼罗病毒、黄热病毒和基孔肯雅热病毒感染药物中的应用 |
| CN115785203B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标10及其用途 |
| CN116606352B (zh) * | 2023-07-14 | 2023-09-29 | 诺赛联合(北京)生物医学科技有限公司 | 一种抗菌修复功能的组合物凝胶在妇科疾病中的应用 |
| WO2025043547A1 (zh) | 2023-08-30 | 2025-03-06 | 杭州高田生物医药有限公司 | T细胞导向免疫脂质体及其用途 |
| KR20250139235A (ko) | 2025-07-15 | 2025-09-23 | 김종구 | V-aemi 기반 인공지능 감정 음악 창작 시스템 및 그 방법 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5728388A (en) | 1989-10-03 | 1998-03-17 | Terman; David S. | Method of cancer treatment |
| GB9323199D0 (en) | 1993-11-10 | 1994-01-05 | Falkenberg J H F | Leukaemia treatment |
| ES2324334T3 (es) * | 1997-12-16 | 2009-08-05 | University Of Zurich | Productos terapeuticos para las celulas t para la encefalopatia espongiforme transmisible y metodo para la fabricacion de productos derivados de tejidos y fluidos corporales no infecciosos. |
| US6406699B1 (en) | 1999-10-05 | 2002-06-18 | Gary W. Wood | Composition and method of cancer antigen immunotherapy |
| US20030099621A1 (en) * | 2001-11-29 | 2003-05-29 | Robert Chow | Stem cell screening and transplantation therapy for HIV infection |
| IL146970A0 (en) | 2001-12-06 | 2002-08-14 | Yeda Res & Dev | Migration of haematopoietic stem cells and progenitor cells to the liver |
| US7282222B2 (en) | 2002-03-15 | 2007-10-16 | The United States Of America As Represented By The Department Of Veterans Affairs | Methods and compositions for directing cells to target organs |
| DK1505973T3 (da) | 2002-05-17 | 2010-05-31 | Celgene Corp | Kombinationer til behandling af multipelt myelom |
| GB0310593D0 (en) | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
| US20040247574A1 (en) | 2003-05-27 | 2004-12-09 | Christopherson Kent W. | Methods for enhancing stem cell engraftment during transplantation |
| CA2589063C (en) | 2004-12-23 | 2016-08-09 | DePuy Synthes Products, Inc. | Treatment of parkinson's disease and related disorders using postpartum derived cells |
| CA2606081C (en) * | 2005-04-26 | 2013-09-17 | Markus M. Heiss | Combination of the application of antibodies for immunostimulation together with glucocorticoids |
| RU2486204C2 (ru) | 2005-07-22 | 2013-06-27 | Уай'З Терапьютикс Ко., Лтд. | Антитела против сd26 и способы их применения |
| US8278104B2 (en) | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| GB0700058D0 (en) | 2007-01-03 | 2007-02-07 | Scancell Aps | Anti-tumor vaccine based on normal cells |
| WO2008094689A2 (en) | 2007-02-01 | 2008-08-07 | Nephrogen, Llc | Potentiation of stem cell homing and treatment of organ dysfunction or organ failure |
| WO2009142759A1 (en) | 2008-05-23 | 2009-11-26 | Argos Therapeutics, Inc. | Novel soluble cd83 polypeptides, formulations and methods of use |
| US20090299269A1 (en) | 2008-05-29 | 2009-12-03 | John Foley | Vascular stimulation to aid intravascular cell replacement therapy |
| ES2627043T3 (es) | 2008-06-09 | 2017-07-26 | Targazyme, Inc. | Aumento de la eficacia de la terapia celular incluyendo tratamiento con alfa 1-3 fucoslitransferasa |
| WO2009152186A1 (en) | 2008-06-09 | 2009-12-17 | American Stem Cell, Inc. | Methods for enhancing cell therapy efficacy including treatment with cd26 peptidase inhibitors |
| US20100055107A1 (en) * | 2008-07-31 | 2010-03-04 | Defu Zeng | Methods for preventing hematological malignancies and graft versus host disease by anti-cd3 preconditioning |
| US10426740B1 (en) * | 2010-08-18 | 2019-10-01 | Avm Biotechnology, Llc | Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues |
| BR112013003169B1 (pt) * | 2010-08-18 | 2022-05-24 | Theresa Deisher | Uso de um agente terapêutico que inibe a ligação de células-tronco a tecido linfóide |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| JP2014509841A (ja) | 2011-01-18 | 2014-04-24 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 癌を治療するための組成物および方法 |
| EP2532740A1 (en) | 2011-06-11 | 2012-12-12 | Michael Schmück | Antigen-specific CD4+ and CD8+ central-memory T cell preparations for adoptive T cell therapy |
| KR20140060541A (ko) | 2011-09-16 | 2014-05-20 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 rna 조작된 t 세포 |
| US10117896B2 (en) | 2012-10-05 | 2018-11-06 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| SG10202109752XA (en) * | 2014-04-07 | 2021-10-28 | Novartis Ag | Treatment of cancer using anti-cd19 chimeric antigen receptor |
| EP3250602A1 (en) * | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| KR102349677B1 (ko) * | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| AU2017368248A1 (en) * | 2016-11-30 | 2019-06-06 | Intrexon Corporation | Steroid administration and immunotherapy |
| CN110475571B (zh) | 2017-04-01 | 2023-04-04 | Avm生物技术有限责任公司 | 细胞免疫疗法前细胞毒性预调理的替代 |
| EP3488851A1 (en) * | 2018-10-03 | 2019-05-29 | AVM Biotechnology, LLC | Immunoablative therapies |
-
2018
- 2018-03-30 CN CN201880021900.0A patent/CN110475571B/zh active Active
- 2018-03-30 IL IL269209A patent/IL269209B2/en unknown
- 2018-03-30 EP EP18722262.5A patent/EP3490605B1/en active Active
- 2018-03-30 WO PCT/US2018/025517 patent/WO2018183927A1/en not_active Ceased
- 2018-03-30 BR BR112019020214-5A patent/BR112019020214A2/pt not_active Application Discontinuation
- 2018-03-30 CA CA3054443A patent/CA3054443A1/en active Pending
- 2018-03-30 ES ES18722262T patent/ES2954311T3/es active Active
- 2018-03-30 MX MX2019011679A patent/MX2019011679A/es unknown
- 2018-03-30 JP JP2018551293A patent/JP6748221B2/ja active Active
- 2018-03-30 KR KR1020197031661A patent/KR102509006B1/ko active Active
- 2018-03-30 SG SG11201907744QA patent/SG11201907744QA/en unknown
- 2018-03-30 AU AU2018243753A patent/AU2018243753A1/en not_active Abandoned
- 2018-05-10 US US15/976,630 patent/US11219628B2/en active Active
-
2020
- 2020-03-19 JP JP2020049116A patent/JP7162632B2/ja active Active
-
2021
- 2021-12-06 US US17/542,712 patent/US20220160729A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019515888A5 (cg-RX-API-DMAC10.html) | ||
| Takada et al. | Cyclophosphamide for the treatment of systemic lupus erythematosus | |
| Martin | Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing–remitting multiple sclerosis | |
| TW201617093A (zh) | 對抗ｐｄ－１及ｐｄ－ｌ１之拮抗劑與輻射療法組合之治療方法 | |
| RU2014127298A (ru) | Применения иммуноконъюгатов, мишенью которых является cd138 | |
| CN113164497A (zh) | 免疫消融疗法 | |
| JP7389486B2 (ja) | 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤 | |
| Gonsette | Pixantrone (BBR2778): a new immunosuppressant in multiple sclerosis with a low cardiotoxicity | |
| Pitarokoili et al. | Anti-inflammatory and immunomodulatory potential of human immunoglobulin applied intrathecally in Lewis rat experimental autoimmune neuritis | |
| US20210380695A1 (en) | Sting agonist combination treatments with immune checkpoint inhibitors | |
| JP2024540044A5 (cg-RX-API-DMAC10.html) | ||
| Johnke et al. | Response of T lymphocyte populations in prostate cancer patients undergoing radiotherapy: influence of neoajuvant total androgen suppression | |
| US6894038B2 (en) | Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases | |
| CN112773802B (zh) | 一种化合物用于预防或治疗移植物抗宿主病的用途 | |
| JP2023512084A5 (cg-RX-API-DMAC10.html) | ||
| Liu et al. | New developments in post-transplant maintenance treatment of multiple myeloma | |
| Golfier et al. | Antibody therapy maintenance in follicular lymphoma | |
| JP6906154B2 (ja) | 造血幹細胞移植患者の処置 | |
| JP2004523518A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| US20200299399A1 (en) | Treatment of Multiple Sclerosis with Anti-CD52 Antibodies | |
| Routledge | Belantamab mafodotin. Antibody-drug conjugate targeting B-cell maturation antigen (BCMA), Treatment of multiple myeloma | |
| Preparative | Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies | |
| Howard | Nonsteroidal immunosuppressive therapy for myasthenia gravis | |
| TW202320788A (zh) | 用於治療或預防抗宿主病的吡咯并六元雜芳物 | |
| JP2025505381A5 (cg-RX-API-DMAC10.html) |